Incyte's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Incyte Corp. (INCY)

Q1 2012 Earnings Call

April 26, 2012 08:30 am ET

Executives

Paul Friedman, M.D. – President and Chief Executive Officer

Patricia Andrews – Executive Vice President and Chief Commercial Officer

David Hastings – Executive Vice President, Chief Financial Officer

Richard Levy – Executive Vice President, Chief Drug Development and Medical Officer

Pamela Murphy – Vice President, Investor Relations and Corporate Communications

Analysts

Rachel McMinn – Bank of America/Merrill Lynch

Salveen Richter – Canaccord Genuity

Eric Schmidt, PhD – Cowen & Co.

Sapna Srivastava – Goldman Sachs

Thomas Wei – Jefferies & Co

Liisa Bayko – JMP Securities

Cory Kasimov – JP Morgan Chase

David Friedman, MD – Morgan Stanley

Matt Roden, PhD – UBS

Brian Abrahams, MD – Wells Fargo Securities

Ying Wang – Barclays Capital

Elliott Savis [ph] – Savis Research [ph]

Presentation

Operator

Greetings, ladies and gentlemen, and welcome to the Incyte Corporation First Quarter 2012 Financial Results Conference Call. A question and answer session will follow the formal presentation. (Operator instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Ms. Pamela Murphy, Vice President, Investor Relations and Communications. Thank you, Ms. Murphy. You may begin.

Pamela Murphy

Good morning and welcome. With me today are Paul Friedman, Incyte’s President and Chief Executive Officer; Pat Andrews, Executive Vice President and Chief Commercial Officer; Dave Hastings, Executive Vice President, Chief Financial Officer; and Rich Levy, Executive Vice President, Chief Drug Development and Medical Officer.

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Cramer: There Should Be More Takeovers Where These Came From

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)